Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice
The DOI matches its Crossref record.
Abstract
BACKGROUND: Conventional antidepressants lack efficacy for many patients (treatmentresistant depression or TRD) and generally take weeks to produce full therapeutic response in others. Emerging data has identified certain drugs such as ketamine as rapidly-acting antidepressants for major depressive disorder and TRD. Scopolamine, a drug used to treat motion sickness and nausea, has also been demonstrated to function as a rapidly-acting antidepressant. The mechanisms associated with efficacy in TRD patients and rapid onset of action have been suggested to involve a-Amino-3-hydroxy- 5-methyl-4-isoxazolepropionic acid (AMPA) receptor and mammalian target of rapamycin (mTOR) signaling. Since the work on these mechanisms with scopolamine has been limited, the present set of experiments was designed to further explore these mechanisms of action. METHOD: Male, NIH Swiss mice demonstrated a robust and immediate antidepressant signature with ketamine or scopolamine when studied under the forced-swim test. RESULTS: The AMPA receptor antagonist NBQX prevented this antidepressant-like effect of scopolamine and ketamine. An orally-bioavilable mTOR inhibitor (AZD8055) also attenuated the antidepressant- like effects of scopolamine and ketamine. Scopolamine was also shown to augment the antidepressant- like effect of the selective serotonin reuptake inhibitor citalopram. When given in combination, scopolamine and ketamine acted synergistically to produce antidepressant-like effects. Although drug interaction data suggested that additional mechanisms might be at play, metabolomic analysis of frontal cortex and plasma from muscarinic M1+/+ and M1 -/- mice given scopolamine or vehicle did not reveal any hints as to the nature of these additional mechanisms of action. CONCLUSION: Overall, the data substantiate and extend the idea that AMPA and mTOR signaling pathways are necessary for the antidepressant-like effects of scopolamine and ketamine, mechanisms that appear to be of general significance for TRD therapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Widman, A. J., & McMahon, L. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718883115 · Cited by 204
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171
“In rodent pre-clinical studies, administration of the AMPAR antagonist NBQX prevents the antidepressant actions of ketamine [45, 47, 64, 195, 244–247], GluN2BNMDAR antagonists [47], 4-chlorokynurenic acid [46], GLYX-13 [57], scopolamine [85, 248], mGluR2/3 antagonists [244, 249], GABAAR-NAMs [164], and (2R,6R)HNK [45].”
BackgroundEmpirical validation of a touchscreen probabilistic reward task in rats
Kangas, B. D., Wooldridge, L. M., Luc, O. T., Bergman, J., & Pizzagalli, D. A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-00969-1 · Cited by 47
Witkin, J. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172854 · Cited by 36
Self-citation
Metadata
- Authors
- Martin, A. E., Schober, D. A., Nikolayev, A., Tolstikov, V. V., Anderson, W. H., Higgs, R. E., Kuo, M.-S., Laksmanan, A., Catlow, J. T., Li, X., Felder, C. C., & Witkin, J. M.
- Venue
- CNS & Neurological Disorders - Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2017-07-05
- Volume
- 16
- Issue
- 4
- Pages
- 492-500
- ISSN
- 1568-007X (ISSN-L)
- 1871-5273
- OpenAlex
- W2610214294
- Cited by
- 35
- References
- 0
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice. https://app.cochat.ai/papers/10.2174/1871527316666170309142646
- The paper
- Martin, A. E., Schober, D. A., Nikolayev, A., Tolstikov, V. V., Anderson, W. H., Higgs, R. E., Kuo, M.-S., Laksmanan, A., Catlow, J. T., Li, X., Felder, C. C., & Witkin, J. M. (2017). Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice. CNS & Neurological Disorders - Drug Targets. https://doi.org/10.2174/1871527316666170309142646
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.